Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 893

Sort by

Sort Order Select

Journal Articles

The role of AGK in thrombocytopoiesis and possible therapeutic strategies

Haojie Jiang, Zhuo Yu, Nan Ding, Mina Yang, Lin Zhang, Xuemei Fan, Yuan Zhou, Qiang Zou, Jian Hou, Junke Zheng, Lei Zhang, Yanyan Xu, Junling Liu

Blood (2020) 136 (1): 119–129.

https://doi.org/10.1182/blood.2019003851

Published: 2020

Includes: Supplemental data

Journal Articles

High Rates of Venous and Arterial Thrombotic Events in POEMS Patients: Results from the UK-Based POEMS Registry, Highlighting the Need for Therapeutic Guidelines

Zara Sayar, MD FRCPath, MRCP, Anna Weatherill, Stephen Keddie, Jonathan Sive, MD, Michael P Lunn, Mari Thomas, Shirley D'Sa

Blood (2019) 134 (Supplement_1): 714.

https://doi.org/10.1182/blood-2019-125639

Published: 2019

Journal Articles

Recombinant Interferon-α Reduces Thrombotic Events in Patients with Polycythemia Vera

Spencer Krichevsky, BS, Ghaith Abu Zeinah, MD, Claudia Sosner, BA, Diana Jaber, BA, Niamh Savage, BA, Gabriela Hoberman, BA, Ellen K. Ritchie, MD, Andrew I. Schafer, MD, Richard T. Silver, MD, Joseph Scandura, MD PhD

Blood (2019) 134 (Supplement_1): 1664.

https://doi.org/10.1182/blood-2019-131605

Published: 2019

Journal Articles

Patient-Reported Outcomes (PRO) Data from Patients (Pts) with Essential Thrombocythemia (ET) Enrolled in the MOST Study

Ellen K. Ritchie, MD, Anas Al-Janadi, MD, Philomena Colucci, DO, MS, Patricia Kalafut, PhD, Dilan Paranagama, PhD, Ruben A. Mesa, MD

Blood (2019) 134 (Supplement_1): 1665.

https://doi.org/10.1182/blood-2019-124527

Published: 2019

Journal Articles

JAK2V617F-Mediated Endothelial Dysfunction Promotes Congestive Heart Failure in a Murine Model of Myeloproliferative Neoplasm

Melissa Castiglione, BS, Christopher Mazzeo, BS, Ya-Ping Jiang, Juei-Suei Chen, Wei Yin, Richard Lin, Huichun Zhan, MD

Blood (2019) 134 (Supplement_1): 7.

https://doi.org/10.1182/blood-2019-131372

Published: 2019

Journal Articles

Real World Data on Obstetric (OC) and Maternal Complications (MC) Occurring in a Cohort of Patients with Ph Negative Myeloproliferative Neoplasms (MPN): Argentinian Multicentric Study

Blood (2019) 134 (Supplement_1): 1669.

https://doi.org/10.1182/blood-2019-131778

Published: 2019

Journal Articles

Evaluation of Japanese and International Diagnostic Criteria for Idiopathic Castleman Disease

Makoto Ide, MD

Blood (2019) 134 (Supplement_1): 4873.

https://doi.org/10.1182/blood-2019-128212

Published: 2019

Journal Articles

Spectrum of Abnormalities and Clonal Transformation in Germline RUNX1 Familial Platelet Disorder and a Comparative Analysis with Somatic RUNX1 Mutations in Myeloid Neoplasms

Emma Difilippo, BS, Giacomo Coltro, MD, Ryan M. Carr, MD PhD, Abhishek A Mangaonkar, MBBS, Moritz Binder, MDMPH, Shakila P Khan, MD, Vilmarie Rodriguez, MD, Naseema Gangat, MBBS, Alexandra Wolanskyj, MD, Rajiv K. Pruthi, MBBS, Dong Chen, MD PhD, Rong He, MD, David S Viswanatha, MD, Terra Lasho, PhD, Christy Finke, BS, Ayalew Tefferi, MD, Animesh Pardanani, MBBS, PhD, Mark Litzow, MD, Mrinal M Patnaik, MDMBBS

Blood (2019) 134 (Supplement_1): 3003.

https://doi.org/10.1182/blood-2019-124830

Published: 2019

Journal Articles

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Regina Garcia-Delgado, MD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, László Rejtő, Eric Jourdan, MD, Haifa Kathrin Al-Ali, MD, Andrzej Pluta, MD, Marek Hus, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Irum Khan, MD, Holger Hebart, Philipp J. Jost, MD, Sebastian Grosicki, MD PhD, Wayne M. Rothbaum, Jesse McGreivy, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 2945.

https://doi.org/10.1182/blood-2019-123836

Published: 2019

Journal Articles

Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group

Blood (2019) 134 (Supplement_1): 2946.

https://doi.org/10.1182/blood-2019-124854

Published: 2019

Journal Articles

Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients

Blood (2019) 134 (Supplement_1): 3005.

https://doi.org/10.1182/blood-2019-124115

Published: 2019

Journal Articles

Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea

Byung-Hyun Lee, MD, Hyemi Moon, Ka-Won Kang, Byung Soo Kim, Yong Park

Blood (2019) 134 (Supplement_1): 2951.

https://doi.org/10.1182/blood-2019-122156

Published: 2019

Journal Articles

Baseline Mutational Status of Patients with Myelofibrosis and Anemia in the Realise Trial and Impact on Outcome

Haifa Kathrin Al-Ali, MD, Heinz Gisslinger, MD, Francesco Passamonti, MD, Lynda Foltz, MD FRCPC, David M Ross, MD PhD, Nicola Vianelli, MD, Alessandro M. Vannucchi, MD, Norio Komatsu, MD PhD, Pierre Zachée, Ranjan Tiwari, MSc, Evren Zor, MD, Shalini Chaturvedi, Geralyn Gilotti, MSc, Francisco Cervantes, MD

Blood (2019) 134 (Supplement_1): 2952.

https://doi.org/10.1182/blood-2019-124739

Published: 2019

Journal Articles

Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, Philomena Colucci, DO, MS, Dilan Paranagama, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 2948.

https://doi.org/10.1182/blood-2019-124343

Published: 2019

Journal Articles

Eltrombopag for Immune Thrombocytopenia Adult Patients in the Real-Life Practice in France. Interim Results of the Elextra Study

Guillaume Moulis, MD PhD, Manuela Rueter, MSc, Margaux Lafaurie, PharmD, Maryse Lapeyre-Mestre, MD PhD, Carmen investigators Group

Blood (2019) 134 (Supplement_1): 2372.

https://doi.org/10.1182/blood-2019-126000

Published: 2019

Journal Articles

Megakaryocyte Ablation Ameliorates Bone Marrow Fibrosis By Reducing Myofibroblast Differentiation in a Mouse Model of Primary Myelofibrosis

Yutein Chung, PhD, Huiyan Jin, PhD, Claire Trasorras, Francina Gonzalez, Sang Hee Min, MD PhD

Blood (2019) 134 (Supplement_1): 2493.

https://doi.org/10.1182/blood-2019-132186

Published: 2019

Journal Articles

The High Mobility Group A1 Chromatin Regulator Is Required for Pathologic Megakaryocyte Development and Progression to Myelofibrosis in JAK2V617F Murine Models

Alison R. Moliterno, MD, Donna Marie Williams, PhD, Liping Li, MD PhD, Lingling Xian, MD PhD, Li Luo, PhD, Amy S. Duffield, MD PhD, Ophelia Rogers, Jerry L. Spivak, MD, Linda Resar, MD

Blood (2019) 134 (Supplement_1): 472.

https://doi.org/10.1182/blood-2019-131432

Published: 2019

Journal Articles

Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis

Claire N Harrison, Professor, Jacqueline S Garcia, MD, Ruben A Mesa, MD, Tim CP Somervaille, MD PhD, Rami S. Komrokji, MD, Naveen Pemmaraju, MD, Catriona Jamieson, MD PhD, Nikolaos Papadantonakis, MDPhDMSc, James M. Foran, MD, Casey L. O'Connell, MD, Leanne Holes, BS, MBA,, Jia Jia, PhD MBA, Jason Harb, PhD, Jessica Hutti, PhD, Josef T. Prchal, MD

Blood (2019) 134 (Supplement_1): 671.

https://doi.org/10.1182/blood-2019-130158

Published: 2019

Journal Articles

Disease Phenotype and Clonal Amplification in Calreticulin del52 and ins5 Knock-in Mice Are Dependent on the Type of Mutations and Gene Dosage

Camélia Benlabiod, Maira da Costa Cacemiro, PhD, Thomas Balligand, MD, Barbara Panneau-Schmaltz, PhD, Delphine Muller, Laure Touchard, Patrick Gonin, DVM, Jean-Luc Villeval, PhD, Stefan N Constantinescu, MD PhD, Hana Raslova, PhD, William Vainchenker, MD PhD, Isabelle Plo, Caroline Marty, PhD

Blood (2019) 134 (Supplement_1): 311.

https://doi.org/10.1182/blood-2019-127918

Published: 2019

Journal Articles

Depletion of Neoplastic CD11b Positive Cells in Jak2 V617F Mutant Mice Reduced Fibrocytes in Bone Marrow and Improved Myelofibrosis

Yoshinori Ozono, MD, Kotaro Shide, MD PhD, Takuro Kameda, MD PhD, Ayako Kamiunten, MD, Yuki Tahira, MD, Masaaki Sekine, MD, Keiichi Akizuki, MD, Kenichi Nakamura, MD, Hisayoshi Iwakiri, MD, Tomonori Hidaka, MD, Yoko Kubuki, MD PhD, Satoru Hasuike, MD PhD, Fumiyo Toyoshima, MD PhD, Akira Sawaguchi, MD PhD, Kenji Nagata, MD PhD, Kazuya Shimoda, MD PhD

Blood (2019) 134 (Supplement_1): 310.

https://doi.org/10.1182/blood-2019-130042

Published: 2019

NARROW

The role of AGK in thrombocytopoiesis and possible therapeutic strategies

High Rates of Venous and Arterial Thrombotic Events in POEMS Patients: Results from the UK-Based POEMS Registry, Highlighting the Need for Therapeutic Guidelines

Recombinant Interferon-α Reduces Thrombotic Events in Patients with Polycythemia Vera

Patient-Reported Outcomes (PRO) Data from Patients (Pts) with Essential Thrombocythemia (ET) Enrolled in the MOST Study

JAK2V617F-Mediated Endothelial Dysfunction Promotes Congestive Heart Failure in a Murine Model of Myeloproliferative Neoplasm

Real World Data on Obstetric (OC) and Maternal Complications (MC) Occurring in a Cohort of Patients with Ph Negative Myeloproliferative Neoplasms (MPN): Argentinian Multicentric Study

Evaluation of Japanese and International Diagnostic Criteria for Idiopathic Castleman Disease

Spectrum of Abnormalities and Clonal Transformation in Germline RUNX1 Familial Platelet Disorder and a Comparative Analysis with Somatic RUNX1 Mutations in Myeloid Neoplasms

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group

Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients

Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea

Baseline Mutational Status of Patients with Myelofibrosis and Anemia in the Realise Trial and Impact on Outcome

Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study

Eltrombopag for Immune Thrombocytopenia Adult Patients in the Real-Life Practice in France. Interim Results of the Elextra Study

Megakaryocyte Ablation Ameliorates Bone Marrow Fibrosis By Reducing Myofibroblast Differentiation in a Mouse Model of Primary Myelofibrosis

The High Mobility Group A1 Chromatin Regulator Is Required for Pathologic Megakaryocyte Development and Progression to Myelofibrosis in JAK2V617F Murine Models

Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis

Disease Phenotype and Clonal Amplification in Calreticulin del52 and ins5 Knock-in Mice Are Dependent on the Type of Mutations and Gene Dosage

Depletion of Neoplastic CD11b Positive Cells in Jak2 V617F Mutant Mice Reduced Fibrocytes in Bone Marrow and Improved Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only